SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — May 4, 2017
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: May 4, 2017 · CIK: 0000921114 · Accession: 0001144204-17-024343
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217169
Letter
Via EDGAR Division of Corporation Finance File No. 333-217169 Acceleration Request Requested Date: May 8, 2017 Requested Time: 5:00 P.M. Eastern Time
Dear Ms. Breslin:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-217169) (the “Registration Statement”) to become effective on May 8, 2017, at 5:00 P.M. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”). This request for acceleration is subject, however, to your receiving a telephone call prior to such time from our legal counsel, Cooley LLP, confirming this request. The Registrant hereby authorizes each of Asa Henin and James Pennington of Cooley LLP, counsel to the Registrant, to make such request on its behalf. The Registrant is aware of its obligations under the Securities Act.
Once the Registration Statement has been declared effective, please orally confirm that event with Asa Henin of Cooley LLP, counsel to the Registrant, at (858) 550-6104, or in his absence, James Pennington of Cooley LLP at (858) 550-6029.
Very truly yours,
AmpliPhi Biosciences Corporation
Show Raw Text
CORRESP
1
filename1.htm
3579 Valley Centre, Suite 100
San Diego, CA 92130
Via EDGAR
May 4, 2017
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Mary Beth Breslin
Re: AmpliPhi Biosciences Corporation
Registration Statement on Form S-1
Filed April 6, 2017, as amended
File No. 333-217169
Acceleration Request
Requested
Date: May 8, 2017
Requested
Time: 5:00 P.M. Eastern Time
Dear Ms. Breslin:
In accordance with
Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned registrant
(the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-217169) (the “Registration
Statement”) to become effective on May 8, 2017, at 5:00 P.M. Eastern Time, or as soon thereafter as is practicable,
or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”).
This request for acceleration is subject, however, to your receiving a telephone call prior to such time from our legal counsel,
Cooley LLP, confirming this request. The Registrant hereby authorizes each of Asa Henin and James Pennington of Cooley LLP,
counsel to the Registrant, to make such request on its behalf. The Registrant is aware of its obligations under the Securities
Act.
Once the Registration
Statement has been declared effective, please orally confirm that event with Asa Henin of Cooley LLP, counsel to the Registrant,
at (858) 550-6104, or in his absence, James Pennington of Cooley LLP at (858) 550-6029.
Very truly yours,
AmpliPhi Biosciences Corporation
By:
/s/ M. Scott Salka
M. Scott Salka
Chief Executive Officer
cc: Steve R. Martin, AmpliPhi Biosciences Corporation
Thomas A. Coll, Esq., Cooley LLP
Ivan Blumenthal, Esq., Mintz, Levin,
Cohn, Ferris, Glovsky and Popeo, P.C.
Daniel Bagliebter, Esq., Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C.